RONALD J DANIELS, a director at $BBIO, sold 61,031 shares of the company on 11-06-2025 for an estimated $3,888,999. We received data on the trade from a recent SEC filing. This was a sale of approximately 78.2% of their shares of this class of stock. Following this trade, they now own 16,991 shares of this class of $BBIO stock.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 59 times in the past 6 months. Of those trades, 0 have been purchases and 59 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $205,200,000
- GLOBAL INVESTORS LP VIKING sold 3,500,000 shares for an estimated $154,000,000
- FRANK MCCORMICK has made 0 purchases and 8 sales selling 374,000 shares for an estimated $21,669,536.
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 35 sales selling 447,312 shares for an estimated $20,290,345.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,590 shares for an estimated $2,961,803.
- ANDREA ELLIS sold 17,167 shares for an estimated $841,183
- HANNAH VALANTINE has made 0 purchases and 5 sales selling 8,999 shares for an estimated $379,007.
- MARICEL APULI (Chief Accounting Officer) sold 1,000 shares for an estimated $45,440
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Hedge Fund Activity
We have seen 208 institutional investors add shares of $BBIO stock to their portfolio, and 159 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-31.2%) from their portfolio in Q2 2025, for an estimated $259,080,000
- VIKING GLOBAL INVESTORS LP removed 3,500,000 shares (-15.9%) from their portfolio in Q2 2025, for an estimated $151,130,000
- CITADEL ADVISORS LLC removed 2,598,708 shares (-88.7%) from their portfolio in Q2 2025, for an estimated $112,212,211
- FARALLON CAPITAL MANAGEMENT LLC added 2,169,000 shares (+37.8%) to their portfolio in Q2 2025, for an estimated $93,657,420
- JANUS HENDERSON GROUP PLC added 2,105,133 shares (+29.4%) to their portfolio in Q2 2025, for an estimated $90,899,642
- MACQUARIE GROUP LTD added 2,003,713 shares (+2189.3%) to their portfolio in Q2 2025, for an estimated $86,520,327
- D. E. SHAW & CO., INC. added 1,998,104 shares (+2403.0%) to their portfolio in Q2 2025, for an estimated $86,278,130
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/22, 08/08 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Goldman Sachs issued a "Buy" rating on 10/31/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
- Truist Securities issued a "Buy" rating on 10/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/30/2025
- Piper Sandler issued a "Overweight" rating on 10/30/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 16 analysts offer price targets for $BBIO in the last 6 months, with a median target of $76.5.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $77.0 on 11/07/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $90.0 on 11/03/2025
- Paul Choi from Goldman Sachs set a target price of $100.0 on 10/31/2025
- Tyler Van Buren from TD Cowen set a target price of $95.0 on 10/30/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $110.0 on 10/30/2025
- Biren Amin from Piper Sandler set a target price of $98.0 on 10/30/2025
- Martin Auster from Raymond James set a target price of $71.0 on 10/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
